Patenting stem cells: filing date is the key

In the inaugural issue of the LSIPR quarterly, Andy Sanderson analysed options of obtaining patent protection in the aftermath of the Brüstledecision of the Court of Justice of the European Union (CJEU) that further restricted options of applicants to obtain patent protection for human embryonic stem (hES) cell-related inventions.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sarepta wins $115M in patent dispute over muscular dystrophy drug

CREATES Act unfairly tips the scales to generics

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

Trump’s return sparks calls for pro-patent agenda

Amgen faces pushback over bid to narrow patent scope

LSPN Europe: Navigating the EPO and lessons from the UPC frontline

Patenting stem cells: filing date is the key

Editor's picks

Editor's picks

More features